查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2008677

扩大性心肌病治疗市场：依治疗分类、治疗方法、给药途径、最终用户和分销管道划分－2026-2032年全球市场预测

Dilated Cardiomyopathy Therapeutics Market by Therapeutic Class, Treatment Modality, Route Of Administration, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，扩大性心肌病治疗市场价值将达到 4.9366 亿美元，到 2026 年将成长至 5.3772 亿美元，到 2032 年将达到 7.9062 亿美元，复合年增长率为 6.95%。

主要市场统计数据
基准年 2025 4.9366亿美元
预计年份：2026年 5.3772亿美元
预测年份 2032 7.9062亿美元
复合年增长率 (%) 6.95%

这是一本权威的入门书籍，概述了现代扩大性心肌病治疗的临床复杂性、不断发展的多学科护理和动态创新。

扩大性心肌病（DCM）是一种复杂的临床综合征，其特征是心室扩张和收缩功能障碍，导致不同患者群体出现显着的发病率和死亡率。过去十年，治疗策略已从传统的神经激素阻断疗法扩展到包括先进的器械介入和针对遗传及分子因素的精准医疗。这种发展要求相关人员重新评估诊疗路径、资源分配和长期管理模式，以反映渐进式改善和突破性创新。

医疗器材技术创新、精准生物製药以及医疗保健服务体系的重新设计如何从根本上重塑扩张型心肌病变的治疗路径和相关人员的奖励。

扩大性心肌病的治疗格局正经历一场变革，其驱动力包括技术进步、监管环境的演变以及医疗服务模式的转变。曾经仅用于紧急救生措施的医疗设备，如今正被纳入临床诊疗路径的早期阶段，因为越来越多的证据表明它们对降低发病率和提高生存率具有积极作用。同时，医疗器材的小型化和远端监测技术的进步也正在改变门诊就诊和追踪的频率。

评估 2025 年价格调整将如何重塑全球医疗设备、生物製药和基因治疗材料在心肌病。

将于2025年实施的新关税措施将进一步加剧扩大性心肌病治疗药物的全球供应链和成本结构的复杂性，尤其是在跨境生物製药零件和原材料方面。心臟再同步治疗系统、植入式心臟整流去颤器和心室辅助装置等医疗设备依赖复杂的全球製造网络，该网络供应半导体、感测器和特种合金等零件。上游供应商面临的关税压力可能会蔓延至医疗器材製造商，可能会给医院和采购商带来价格压力。

将治疗分类、治疗方法、给药途径、医疗保健机构和分销管道与临床和商业策略联繫起来的综合细分洞察。

扩大性心肌病观点分析扩张型心肌病变治疗，透过考虑治疗分类、治疗方法、给药途径、终端用户环境和通路，可以揭示不同的机会和应用趋势。将治疗分类细分为ACE抑制剂、ARB、ARNI、 β阻断剂、器械疗法、利尿剂和基因疗法，可以发现，儘管药物治疗仍然至关重要，但器械疗法和基因疗法具有独特的临床和商业性特征。此外，将器械疗法细分为CRT、ICD和VAD，突显了投资和治疗路径的多样化需求。观点治疗方法（器械疗法、基因疗法、药物疗法），并认识到药物研发正在向生物製剂和小分子药物方向发展，可以明确区分哪些领域研发风险和监管复杂性较高，哪些领域更易于进行渐进式临床优化。

区域趋势分析解释了美洲、欧洲、中东和非洲以及亚太地区的监管、报销和基础设施因素如何影响治疗方法。

区域趋势正在以不同的方式影响扩大性心肌病)治疗的研发、引进和应用，美洲、欧洲、中东和非洲 (EMEA) 以及亚太地区的情况。在美洲，成熟的医疗基础设施和完善的报销机制支持先进医疗设备和新一代生物製剂的快速引进，但支付者越来越要求提供严谨的卫生经济学证据来证明高昂治疗费用的合理性。临床网路和高度专业化的中心有助于患者参与复杂的手术和临床试验，而私人和公共保险公司正在就影响商业化策略的福利条件进行谈判。

企业定位与竞争策略：揭示医疗设备领导企业、生技药品开发商和基因治疗先驱如何整合自身能力以确保长期竞争优势。

扩大性心肌病治疗市场格局呈现出多元化大型医疗设备製造商、专业生技药品研发公司和新兴基因治疗创新者策略融合的趋势。成熟的循环系统医疗设备公司持续投资于下一代植入式系统、远端监测生态系统以及治疗前后的服务模式，以改善患者的长期疗效并创造持续的业务收益。这些成熟公司积极寻求补充性收购、合作开发伙伴关係和广泛的临床项目，以拓展业务至相关附加价值服务领域，同时保持其在医疗设备领域的领先地位。

领导者必须应对的策略挑战，以增强证据产生、供应韧性和跨治疗方法和医疗保健环境的全面商业化。

产业领导企业应采取多管齐下的策略，优先考虑证据生成、供应链韧性和整合商业化，以在扩大性心肌病治疗领域获得临床和商业性价值。首先，透过可操作的临床试验、真实世界数据 (RWE) 计画和註册登记来加强证据基础至关重要，这有助于说服临床医生和保险公司相信治疗的额外益处，尤其是在高成本医疗设备和基因疗法领域。建立可互通的数据平台，以促进长期疗效追踪，将有助于开展基于价值的对话和上市后倡议。

透明的调查方法，结合文献综述、相关人员访谈、临床註册分析和情境评估，得出了可靠的策略结论。

本次高阶主管分析的基础研究结合了对同侪审查文献、监管申报文件和临床试验註册库的系统性回顾，以及针对整个生态系统的重点一手研究。文献整合涵盖了最新的指南、共识声明和具有重大影响的临床研究，以确保与目前的医疗标准保持一致。研究人员仔细审查了临床试验註册库和已发布的监管申报文件，以整理医疗设备和基因治疗候选药物的临床实验项目和预期里程碑。

一项权威的综合分析重点阐述了临床创新、证据深度和操作适用性将如何决定未来扩大性心肌病。

扩大性心肌病的治疗方法正处于转折点，器械创新、生物製药的进步以及基因组医学的融合，在拓展治疗可能性的同时，也增加了研发、交付和报销流程的复杂性。能够将临床严谨性与营运灵活性相结合的相关人员，将更有能力将科学进步转化为对患者有意义的治疗效果和永续的商业模式。在瞬息万变的医疗保健格局中，有必要重新评估投资重点，并专注于实证医学的产生、区域价值链策略以及以价值为导向的商业化。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：扩大性心肌病治疗药物市场（依治疗分类）

  • ACE抑制剂
  • ARB
  • ARNI
  • β阻断剂
  • 器械疗法
    • CRT
    • ICD
    • VAD
  • 利尿剂
  • 基因治疗

第九章：扩大性心肌病治疗市场（依治疗方法划分）

  • 器械疗法
  • 基因治疗
  • 药物治疗
    • 生物製药
    • 低分子化合物

第十章：扩大性心肌病治疗市场：依给药途径划分

  • 静脉
  • 口服

第十一章：扩大性心肌病治疗市场：依最终用户划分

  • 居家医疗
  • 医院
  • 专科诊所

第十二章：扩大性心肌病治疗药物市场：依分销管道划分

  • 医院药房
  • 网路药房
  • 零售药房

第十三章：扩大性心肌病治疗药物市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章：扩大性心肌病治疗药物市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章：扩大性心肌病治疗药物市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国扩大性心肌病治疗药物市场

第十七章：中国扩大性心肌病治疗药物市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • AbbVie Inc.
  • Amgen Inc.
  • Amicus Therapeutics
  • Astellas Pharma Inc
  • AstraZeneca plc
  • Bayer AG
  • Biogen Inc.
  • BioMarin Pharmaceutical Inc
  • CH Boehringer Sohn AG & Co. KG
  • Daiichi Sankyo Company, Limited
  • Eli Lilly and Company
  • Gilead Sciences, Inc.
  • GlaxoSmithKline（GSK）
  • Johnson & Johnson Services, Inc.
  • Kyowa Kirin Co, Ltd
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Roche Holding AG
  • Sanofi SA
  • Sarepta Therapeutics
  • Teva Pharmaceutical Industries Ltd.
  • The Bristol-Myers Squibb Company
  • The Takeda Pharmaceutical Company Limited
  • Vertex Pharmaceuticals
  • Viatris Inc.
Product Code: MRR-8E22B61932B4

The Dilated Cardiomyopathy Therapeutics Market was valued at USD 493.66 million in 2025 and is projected to grow to USD 537.72 million in 2026, with a CAGR of 6.95%, reaching USD 790.62 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 493.66 million
Estimated Year [2026] USD 537.72 million
Forecast Year [2032] USD 790.62 million
CAGR (%) 6.95%

An authoritative introduction framing the clinical complexity, multidisciplinary care evolution, and innovation dynamics shaping modern dilated cardiomyopathy therapeutics

Dilated cardiomyopathy (DCM) represents a complex clinical syndrome characterized by ventricular dilation and systolic dysfunction that leads to substantial morbidity and mortality across diverse patient populations. Over the past decade, therapeutic strategies have expanded beyond traditional neurohormonal blockade to include advanced device interventions and precision medicines that target genetic and molecular drivers. This evolution compels stakeholders to reassess care pathways, resource allocation, and long-term management models to reflect both incremental improvements and step-change innovations.

Clinical practice is adapting to a more heterogeneous patient profile, where early identification of genetic etiologies and nuanced phenotyping inform personalized treatment plans. As a result, multidisciplinary teams spanning cardiology, electrophysiology, genetics, and allied health professionals are increasingly central to therapy selection and ongoing monitoring. Payers and health systems are likewise recalibrating coverage frameworks to address up-front costs associated with devices and gene-based interventions while evaluating downstream reductions in hospitalizations and complications.

From an innovation perspective, the interplay between device engineering, biologic therapeutics, and small-molecule optimization has created a richer set of options for clinicians and patients. Consequently, strategic planning in this therapeutic area requires a granular understanding of segment dynamics, regulatory trajectories, clinical trial readouts, and real-world evidence as they converge to influence adoption, care delivery, and investment priorities.

How converging device innovation, precision biologics, and care delivery redesign are fundamentally reshaping therapeutic pathways and stakeholder incentives in dilated cardiomyopathy

The therapeutic landscape for dilated cardiomyopathy is undergoing transformative shifts driven by converging technological advances, regulatory evolution, and changing care delivery models. Devices that once served as rescue interventions are now being integrated earlier in clinical pathways as evidence accumulates about their impact on morbidity and survival, while miniaturization and remote-monitoring capabilities are reshaping outpatient management and follow-up intensity.

Simultaneously, precision medicine is moving from promise to practice. Gene therapies and targeted biologics are advancing through clinical development with increasingly sophisticated patient selection strategies that leverage genetic testing and biomarker profiling. This is accompanied by a rethinking of clinical trial designs toward adaptive models and real-world endpoints that better reflect heterogeneous patient populations. The pharmacological landscape remains important, with refined small molecules and novel biologic constructs aimed at neurohormonal modulation and myocardial remodeling complementing device-based modalities.

Distribution and care settings are being reimagined; hospitals remain centers of acute care and implantation, but a shift toward homecare, remote titration, and specialty clinics for longitudinal management is evident. These delivery changes are enabled by digital health platforms, interoperability between monitoring devices and electronic records, and greater emphasis on patient-reported outcomes. Collectively, these shifts are not incremental but structural, altering how products are developed, positioned, and reimbursed, and placing a premium on integrated strategies that bridge devices, biologics, and services.

Assessment of how 2025 tariff shifts are reshaping global manufacturing, procurement, and pricing strategies across devices, biologics, and gene therapy inputs in cardiomyopathy care

The introduction of new tariff measures in 2025 adds a significant layer of complexity to global supply chains and cost structures in dilated cardiomyopathy therapeutics, particularly for components and biologic inputs that cross international borders. Medical devices such as cardiac resynchronization therapy systems, implantable cardioverter-defibrillators, and ventricular assist devices depend on intricate global manufacturing networks for semiconductors, sensors, and specialized alloys. Tariff-induced cost pressures on upstream suppliers can cascade to device manufacturers, creating potential pricing tensions for hospitals and purchasers.

On the pharmacological and gene therapy side, manufacturing inputs for vectors, viral production, and complex biologic reagents often involve cross-border sourcing of raw materials and specialized processing equipment. Increased import duties or customs friction can lengthen lead times and raise production costs, prompting sponsors to re-evaluate contract manufacturing strategies, regionalize production, or accelerate technology transfers. These operational responses can mitigate exposure but require capital investment and regulatory coordination that take time to realize.

For health systems and payers, the net effect of tariff-driven cost changes may be felt through procurement cycles and capital budgeting for device programs, as well as through negotiated pricing for high-cost biologics and gene-based therapeutics. In response, manufacturers may pursue differentiated pricing models, local manufacturing partnerships, or outcomes-based contracting to preserve access while maintaining commercial viability. Finally, regulatory and reimbursement stakeholders are likely to scrutinize value propositions more closely, linking coverage decisions to robust clinical and economic evidence as part of a broader adaptation to changing input costs.

Integrated segmentation insights that connect therapeutic classes, treatment modalities, administration routes, care settings, and distribution channels to clinical and commercial strategy

A segmentation-aware view of dilated cardiomyopathy therapeutics reveals differentiated opportunities and adoption dynamics when consideration is given to therapeutic class, treatment modality, administration route, end-user environment, and distribution pathway. When therapeutic class is parsed into ACE inhibitor, Arb, Arni, Beta Blocker, Device Therapy, Diuretic, and Gene Therapy, it becomes clear that medical management remains foundational while device therapy and gene therapy introduce distinct clinical and commercial characteristics; further granularity in device therapy across Crt, Icds, and Vad highlights heterogeneous investment and care pathway requirements. Looking through the lens of treatment modality-Device Based, Gene Therapy, and Pharmacological-and recognizing that pharmacological development bifurcates into Biologics and Small Molecule approaches-clarifies where development risk and regulatory complexity converge versus where incremental clinical optimization is more feasible.

Route of administration further stratifies operational considerations: Intravenous modalities carry implications for inpatient or clinic-based delivery infrastructures, whereas Oral therapies enable broader outpatient management and adherence-focused interventions. End user segmentation across Homecare, Hospital, and Specialty Clinic settings emphasizes shifting touchpoints for follow-up, titration, and device monitoring, with homecare growth accelerating needs for remote monitoring and caregiver support. Finally, distribution channel differentiation among Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies shapes logistics, inventory strategies, and patient access patterns, influencing how manufacturers and payers design distribution agreements and patient support programs.

Integrating these segmentation dimensions enables a clearer mapping of clinical value to commercial levers. For example, gene therapy candidates may require specialized distribution and hospital-based administration while oral small molecules can be deployed broadly through retail pharmacies. Devices necessitate capital procurement and post-implant surveillance, elevating the importance of durable service agreements and interoperability with clinical IT systems. Understanding these intersections is critical for prioritizing R&D investments, tailoring market access plans, and designing patient-centered support models.

Regional dynamics analysis describing how heterogeneous regulatory, reimbursement, and infrastructure factors in the Americas, EMEA, and Asia-Pacific influence therapy adoption and access

Regional dynamics are shaping the development, adoption, and delivery of dilated cardiomyopathy therapeutics in distinct ways across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, mature care infrastructures and well-established reimbursement frameworks support rapid adoption of advanced devices and next-generation biologics, though payers increasingly demand rigorous health-economic evidence to justify high-cost interventions. Clinical networks and specialized centers of excellence facilitate complex procedures and clinical trial enrollment, while private and public payers negotiate coverage conditions that influence commercialization strategies.

Across Europe, Middle East & Africa, the region exhibits considerable heterogeneity driven by national regulatory, reimbursement, and health system structures. Western European markets often mirror North American pathways with structured adoption of devices and biologics, whereas emerging markets within the region face capacity constraints that may delay deployment of complex therapies. Policy emphasis on cost-effectiveness and centralized HTA processes shapes pricing strategies and can incentivize local evidence generation or managed entry agreements.

In the Asia-Pacific region, rapid investments in hospital infrastructure and a growing emphasis on cardiovascular disease management are expanding patient access to advanced therapies. Regulatory pathways in several jurisdictions have been modernized to facilitate expedited review for innovative therapeutics, and local manufacturing initiatives are increasingly pursued to reduce import dependency. Regional collaboration and harmonization efforts are creating new avenues for clinical research and could accelerate broader adoption of device-based and gene-focused interventions when combined with strategic partnerships and localized market access approaches.

Corporate positioning and competitive maneuvers revealing how device leaders, biologics developers, and gene therapy pioneers are aligning capabilities for long-term advantage

The corporate landscape in dilated cardiomyopathy therapeutics is marked by strategic convergence between large diversified device manufacturers, specialist biologics developers, and emerging gene therapy innovators. Established cardiovascular device firms continue to invest in next-generation implantable systems, remote monitoring ecosystems, and peri-procedural service models that enhance long-term patient outcomes and create recurring service revenues. These incumbents often pursue bolt-on acquisitions, co-development partnerships, and broad-based clinical programs to sustain device leadership while expanding into adjacent value-added services.

Biopharmaceutical companies with cardiovascular portfolios are diversifying through targeted biologics and small-molecule programs that address myocardial remodeling and neurohormonal pathways. Simultaneously, biotechnology firms focused on gene editing and vectorized gene replacement are advancing candidates that target defined genetic etiologies of dilated cardiomyopathy, fostering collaborations with manufacturing specialists and clinical research networks to manage development complexity and scale-up risks. Cross-sector alliances between device makers and biologic developers are becoming more common, particularly where combination therapies or diagnostic-enabled patient selection can enhance therapeutic impact.

Competitive differentiation increasingly hinges on evidentiary depth, post-market surveillance capabilities, and the ability to demonstrate real-world value. Companies that invest in longitudinal data platforms, patient support programs, and integrated care solutions are better positioned to engage payers and care providers. Moreover, strategic moves such as regional manufacturing investments, outcomes-based contracting pilots, and early engagement with regulatory agencies are shaping which players can effectively translate scientific advances into sustainable commercial success.

Actionable strategic imperatives for leaders to fortify evidence generation, supply resilience, and integrated commercialization across therapeutics and care settings

Industry leaders should pursue a multi-dimensional strategy that prioritizes evidence generation, supply chain resilience, and integrated commercialization to capture clinical and commercial value in dilated cardiomyopathy therapeutics. First, strengthening the evidence base through pragmatic trials, real-world evidence programs, and registries will be essential to convince clinicians and payers of incremental benefits, particularly for high-cost devices and gene-based therapies. Building interoperable data platforms that facilitate long-term outcome tracking will support value-based conversations and post-market commitments.

Second, diversifying manufacturing footprints and establishing qualified regional partners can mitigate tariff and logistics risks while reducing lead times for critical inputs. Investing in technology transfer and quality systems in strategically selected regions will enable faster response to demand shifts and regulatory requirements. Third, commercial strategies must be aligned to care settings: tailored access programs for hospital procurement, streamlined pathways for specialty clinics, and patient adherence solutions for oral therapies will improve uptake across end-user segments.

Finally, forging cross-sector partnerships-linking device capabilities with pharmacological innovations and digital health tools-can create differentiated offerings that address both clinical and operational pain points. Leaders should also engage early with regulators and HTA bodies to co-design evidence packages and explore innovative reimbursement arrangements. Executed together, these actions will help organizations navigate evolving policy environments, demonstrate sustainable value, and enhance patient access to advanced therapies.

Transparent methodology integrating literature synthesis, stakeholder interviews, clinical registry analysis, and scenario evaluations to support robust strategic conclusions

The research underpinning this executive analysis combined a structured review of peer-reviewed literature, regulatory filings, and clinical trial registries with targeted primary engagements across the ecosystem. Literature synthesis included recent guidelines, consensus statements, and high-impact clinical studies to ensure alignment with current standards of care. Clinical trial registries and public regulatory filings were examined to map investigational programs and expected milestones for device and gene therapy candidates.

Primary research consisted of interviews with cardiologists, electrophysiologists, health system procurement leads, clinical researchers, and patient advocacy representatives to capture front-line perspectives on adoption barriers and clinical unmet needs. These qualitative insights were triangulated with secondary sources, including manufacturing and supply chain publications, technology briefs, and policy analyses, to assemble a holistic view of operational and regulatory dynamics. Data quality protocols involved cross-validation of key assertions against multiple independent sources and sensitivity checks to identify areas of higher uncertainty.

Analytical approaches included segmentation mapping across therapeutic class, modality, administration route, end user, and distribution channel, as well as scenario-based assessment of tariff and supply chain impacts. The methodology emphasized transparency in assumptions and explicit documentation of evidence sources to facilitate verification and to support subsequent deep-dive investigations.

A conclusive synthesis highlighting how clinical innovation, evidence depth, and operational adaptability will determine future adoption and access in dilated cardiomyopathy care

Dilated cardiomyopathy therapeutics are at an inflection point where device innovation, biologic advancement, and genomic medicine are converging to expand treatment possibilities while simultaneously increasing complexity across development, delivery, and reimbursement pathways. Stakeholders who can integrate clinical rigor with operational agility will be best positioned to translate scientific progress into meaningful patient outcomes and sustainable commercial models. The evolving care landscape requires a recalibration of investment priorities, with emphasis on evidence generation, regional supply chain strategies, and value-aligned commercialization.

Adoption trajectories will be shaped not only by clinical efficacy but also by the ability to demonstrate real-world benefit, manage total cost of care, and adapt to shifting policy environments such as tariff-induced supply changes and evolving HTA expectations. Cross-disciplinary collaboration among clinicians, manufacturers, payers, and regulators will be essential to navigate these dynamics and to create durable pathways for patient access. Ultimately, the organizations that combine scientific excellence with pragmatic delivery models and strong stakeholder engagement will set the cadence for the next era of dilated cardiomyopathy care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Dilated Cardiomyopathy Therapeutics Market, by Therapeutic Class

  • 8.1. ACE Inhibitor
  • 8.2. ARB
  • 8.3. ARNI
  • 8.4. Beta Blocker
  • 8.5. Device Therapy
    • 8.5.1. CRT
    • 8.5.2. ICDS
    • 8.5.3. VAD
  • 8.6. Diuretic
  • 8.7. Gene Therapy

9. Dilated Cardiomyopathy Therapeutics Market, by Treatment Modality

  • 9.1. Device Based
  • 9.2. Gene Therapy
  • 9.3. Pharmacological
    • 9.3.1. Biologics
    • 9.3.2. Small Molecule

10. Dilated Cardiomyopathy Therapeutics Market, by Route Of Administration

  • 10.1. Intravenous
  • 10.2. Oral

11. Dilated Cardiomyopathy Therapeutics Market, by End User

  • 11.1. Homecare
  • 11.2. Hospital
  • 11.3. Specialty Clinic

12. Dilated Cardiomyopathy Therapeutics Market, by Distribution Channel

  • 12.1. Hospital Pharmacies
  • 12.2. Online Pharmacies
  • 12.3. Retail Pharmacies

13. Dilated Cardiomyopathy Therapeutics Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Dilated Cardiomyopathy Therapeutics Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Dilated Cardiomyopathy Therapeutics Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Dilated Cardiomyopathy Therapeutics Market

17. China Dilated Cardiomyopathy Therapeutics Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. AbbVie Inc.
  • 18.6. Amgen Inc.
  • 18.7. Amicus Therapeutics
  • 18.8. Astellas Pharma Inc
  • 18.9. AstraZeneca plc
  • 18.10. Bayer AG
  • 18.11. Biogen Inc.
  • 18.12. BioMarin Pharmaceutical Inc
  • 18.13. C.H. Boehringer Sohn AG & Co. KG
  • 18.14. Daiichi Sankyo Company, Limited
  • 18.15. Eli Lilly and Company
  • 18.16. Gilead Sciences, Inc.
  • 18.17. GlaxoSmithKline (GSK)
  • 18.18. Johnson & Johnson Services, Inc.
  • 18.19. Kyowa Kirin Co, Ltd
  • 18.20. Merck & Co., Inc.
  • 18.21. Novartis AG
  • 18.22. Pfizer Inc.
  • 18.23. Regeneron Pharmaceuticals, Inc.
  • 18.24. Roche Holding AG
  • 18.25. Sanofi S.A.
  • 18.26. Sarepta Therapeutics
  • 18.27. Teva Pharmaceutical Industries Ltd.
  • 18.28. The Bristol-Myers Squibb Company
  • 18.29. The Takeda Pharmaceutical Company Limited
  • 18.30. Vertex Pharmaceuticals
  • 18.31. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT MODALITY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ACE INHIBITOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ACE INHIBITOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ACE INHIBITOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ARB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ARB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ARB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ARNI, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ARNI, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ARNI, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY BETA BLOCKER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY BETA BLOCKER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY BETA BLOCKER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DEVICE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DEVICE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DEVICE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DEVICE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY CRT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY CRT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY CRT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ICDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ICDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ICDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY VAD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY VAD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY VAD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DIURETIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DIURETIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DIURETIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DEVICE BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DEVICE BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DEVICE BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY HOMECARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY HOMECARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY HOMECARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DEVICE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DEVICE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DEVICE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DEVICE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DEVICE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DEVICE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 124. MIDDLE EAST DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 127. AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 129. AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DEVICE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 130. AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 132. AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 133. AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 134. AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DEVICE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. ASEAN DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 146. ASEAN DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DEVICE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 149. ASEAN DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 150. ASEAN DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 151. ASEAN DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 152. GCC DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. GCC DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 154. GCC DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DEVICE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 155. GCC DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 156. GCC DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 157. GCC DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 158. GCC DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 159. GCC DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPEAN UNION DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPEAN UNION DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPEAN UNION DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DEVICE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPEAN UNION DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPEAN UNION DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPEAN UNION DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPEAN UNION DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPEAN UNION DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 168. BRICS DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. BRICS DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 170. BRICS DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DEVICE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 171. BRICS DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 172. BRICS DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 173. BRICS DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 174. BRICS DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 175. BRICS DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 176. G7 DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 177. G7 DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 178. G7 DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DEVICE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 179. G7 DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 180. G7 DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 181. G7 DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 182. G7 DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 183. G7 DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 184. NATO DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 185. NATO DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 186. NATO DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DEVICE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 187. NATO DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 188. NATO DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 189. NATO DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 190. NATO DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 191. NATO DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 192. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. UNITED STATES DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 194. UNITED STATES DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 195. UNITED STATES DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DEVICE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 196. UNITED STATES DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 197. UNITED STATES DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 198. UNITED STATES DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 199. UNITED STATES DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 200. UNITED STATES DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 201. CHINA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 202. CHINA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 203. CHINA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DEVICE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 204. CHINA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 205. CHINA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 206. CHINA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 207. CHINA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 208. CHINA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)